Journal
WORLD ALLERGY ORGANIZATION JOURNAL
Volume 4, Issue -, Pages 54-64Publisher
BMC
DOI: 10.1097/WOX.0b013e31821188e0
Keywords
interleukin-13; asthma; airway hyper-reactivity; fibrosis; single nucleotide polymorphism
Categories
Ask authors/readers for more resources
Asthma affects nearly 300 million people worldwide. The majority respond to inhaled corticosteroid treatment with or without beta-adrenergic agonists. However, a subset of 5 to 10% with severe asthma do not respond optimally to these medications. Different phenotypes of asthma may explain why current therapies show limited benefits in subgroups of patients. Interleukin-13 is implicated as a central regulator in IgE synthesis, mucus hypersecretion, airway hyperresponsiveness, and fibrosis. Promising research suggests that the interleukin-13 pathway may be an important target in the treatment of the different asthma phenotypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available